Crossmark

Severe malaria treatment with rectal artesunate and artemisinin-based combination therapy in remote settings: an effectiveness-implementation hybrid type 3 study protocol (SEMA ReACT)

Crossref DOI link: https://doi.org/10.1186/s12936-026-05816-0

Published Online: 2026-02-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hachizovu, Sebastian

Manyando, Christine

Nambozi, Michael

Khondowe, Shepherd

Hamainza, Busiku

Mukumbuta, Donald

Rietveld, Hans

Mukomena Sompwe, Eric

Kikunda, Ghislain

Muhindo-Mavoko, Hypolite

Luzolo Khote, Flory

Kanyamukenge, Deborah

Bastiaens, Hilde

Kakudji, Aimé

Maseko, Tafadzwa

Makenga, Geofrey

Baraka, Vito

Mutombo, Augustin

Duparc, Stephan

Van Geertruyden, Jean Pierre
License Information

Text and Data Mining valid from 2026-02-09

Version of Record valid from 2026-03-03
More Information

Article History

Received: 22 October 2025

Accepted: 30 January 2026

First Online: 9 February 2026

Declarations

:

: The original protocol and its amendment were approved by the National Health Research Ethics Board in Zambia (reference number NHREB001/15/04/2024 and Ref No: NHRA-2221/13/05/2025) and the Comité National d’Ethique de la Santé in the Democratic Republic of Congo (reference number 502/CNES/BN/PMMF/2023 and 668/CNES/BN/PMMF/2025). The protocol was also approved by the Zambia Medicines Regulatory Authority in Zambia. The study is registered at ClinicalTrials.gov (identifier NCT06806956).

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below